title: Herpesvirus-mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter.
abstract: 1. Herpesvirus infection with genetically engineered vectors is a way to deliver foreign gene products to various cell populations in culture and in vivo. Selective neuronal gene expression can be achieved using the neuron-specific enolase (NSE) promoter regulating expression of a transgene placed in and delivered by a herpesvirus vector. 2. We sought to determine the anatomical specificity and efficiency of herpesvirus-mediated gene transfer into the rat brain following placement of virus particles carrying a transgene (lacZ) under control of the NSE promoter. The virus utilized was thymidine kinase (TK) deficient and therefore replication deficient in the brain. 3. Infusion of 10(6) plaque-forming units of virus into the striatum caused a limited number of striatal neurons to express the lacZ transgene mRNA and protein product 7 days postinfection. In addition, small numbers of neurons expressing the transgene mRNA and protein were found ipsilateral to the viral injection in the frontal cortex, substantia nigra pars compacta, and thalamus. Neurons at these anatomic loci project directly to the striatal injection site. No other cells within the brains of injected animals expressed the lacZ gene. 4. While this herpesvirus NSE vector was capable of introducing novel functional genetic information into postmitotic neurons within defined neuroanatomic constraints, the numbers of neurons expressing detectable levels of beta-galactosidase was minimal. The calculated efficiency of delivery and transgene expression at 7 days postinfection was 1 transgenic neuron per 10(4) virus particles infused. 5. We conclude that NSE probably is not an optimal promoter for use in gene delivery to CNS neurons in herpesvirus vectors and that the efficacy of gene delivery using other neuron-specific promoters placed at various sites in the herpes viral genome needs to be explored.
authors.affiliation: Molecular Neurogenetics Unit, Massachusetts General Hospital, Harvard Medical School, Boston 02128.
authors.forename: J K
authors.initials: JK
authors.lastname: Andersen
authors.forename: D M
authors.initials: DM
authors.lastname: Frim
authors.forename: O
authors.initials: O
authors.lastname: Isacson
authors.forename: X O
authors.initials: XO
authors.lastname: Breakefield
mesh_terms: D000818:Animals; D001483:Base Sequence; D001921:Brain / Q000378:metabolism*; D017931:DNA Primers; D018076:DNA, Complementary / Q000378:metabolism; D004745:Enkephalins / Q000235:genetics; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006801:Humans; D017403:In Situ Hybridization; D008969:Molecular Sequence Data; D009928:Organ Specificity; D010751:Phosphopyruvate Hydratase / Q000235:genetics*; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic; D051381:Rats; D018139:Simplexvirus; D013937:Thymidine Kinase / Q000235:genetics; D014709:Vero Cells; D001616:beta-Galactosidase / Q000096:biosynthesis / Q000235:genetics*
chemical_list: D017931:DNA Primers; D018076:DNA, Complementary; D004745:Enkephalins; D013937:Thymidine Kinase; D001616:beta-Galactosidase; D010751:Phosphopyruvate Hydratase